Deep brain stimulator (DBS) therapy was approved by the FDA in 1997 for the treatment of severe benign essential tremor (essential tremor, familial tremor.) Subsequently in 2002, DBS therapy was approved for use in Parkinson disease to control the various movement disorders associated with this condition. These movement disorders included tremor, dyskinesias, freezing and sudden “off time.” Activa therapy (as it is also known) has proven to be of great benefit to patients with essential tremor who do not respond to medications. This therapy has also greatly improved the quality of life of Parkinson patients who are proper candidates for this type of treatment.